News

Ketamine Advances as Treatment for Levodopa-induced Dyskinesia

The U.S. Food and Drug Administration (FDA) has approved PharmaTher‘s investigational new drug (IND) application for ketamine as a treatment for levodopa-induced dyskinesia in people with Parkinson’s disease. The approval clears the way for PharmaTher to proceed with a Phase 2 clinical trial to study low-dose ketamine —…

Anxiety May Be Unique for Each Patient

Anxiety appears to worsen the physical and cognitive symptoms of Parkinson’s disease, despite the various ways that individuals experience it, according to a recent study. Researchers and healthcare professionals, the study concluded, should take these personal experiences into account when crafting both individual therapies and future research. The study,…

Non-motor Symptoms Determine Quality of Life After DBS

Non-motor symptoms are major determinants of quality of life (QOL) for people with Parkinson’s disease who have undergone deep brain stimulation, known as DBS, a new study reports. “Postoperative QOL was associated with non-motor symptoms … rather than motor symptoms,” the researchers found, specifically noting that patients with…

New Rasagiline Formulation May Allow Application to Skin

A new formulation of rasagiline, approved for Parkinson’s disease, may allow the therapy to be given by applying it to the skin. The treatment’s new formulation was described in the European Journal of Pharmaceutics and Biopharmaceutics, in a study titled “Microemulsion-based gel for the…